ATP5IF1 and acute myeloid leukemia: Continuous exposure to the mitochondrial damaging chemotherapeutic venetoclax positively selected for chemoresistant AML cells with the following characteristics: (i) up-regulated expression of the mitochondrial F1-ATPase and (ii) down-regulation of ATP5IF1.